Biogen Inc. (BIIB): George A Scangos , Chief Executive Officer of Biogen Inc. sold 487 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 4, 2016 to the Securities and Exchange Commission. The shares were sold at $274.74 per share for a total value of $133,798.38 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 7, 2016, Adam Koppel (EVP, Strategy and Bus. Dev.) sold 102 shares at $275.00 per share price.On Apr 7, 2016, George A Scangos (Chief Executive Officer) sold 157 shares at $280.00 per share price.Also, On Feb 26, 2016, Alfred Sandrock (EVP CMO Neuro & Neurodegenerat) sold 183 shares at $261.90 per share price.On Dec 3, 2015, Adriana Karaboutis (EVP, Tech. and Bus. Solutions) sold 48 shares at $289.14 per share price.
Shares of Biogen Inc (BIIB) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -10.59 points or -3.87% at $263.12 with 17,88,237 shares getting traded. Post opening the session at $271.7, the shares hit an intraday low of $262.44 and an intraday high of $271.75 and the price vacillated in this range throughout the day. The company has a market cap of $57,637 M and the number of outstanding shares has been calculated to be 21,90,51,490 shares. The 52-week high of Biogen Inc is $420.99 and the 52-week low is $242.07.
Company has been under the radar of several Street Analysts.Biogen Inc is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $345. The Rating was issued on Feb 25, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.